


México

Region of the Americas



I. Epidemiological profile

Population (UN Population Division)	2017	%	Parasites and vectors
Number of active foci	46	-	Major plasmodium species:
Number of people living within active foci	4.2M	3	P.falciparum: 0 (%) , P.vivax: 100 (%)
Malaria free (0 cases)	125M	97	Major anopheles species:
Total	125M		<i>An. pseudopunctipennis</i> , <i>An. albimanus</i> , <i>An. darlingi</i> , <i>An. punctimacula</i> , <i>An. punctimacula</i>
Reported cases and deaths			
Reported indigenous confirmed cases (health facility):	736		
Confirmed cases at community level:	-		
Confirmed cases from private sector:	6		
Indigenous deaths:	0		

II. Intervention policies and strategies

Intervention	Policies/Strategies	Yes/No	Year adopted	Antimalaria treatment policy	Medicine	Year adopted
ITN	ITNs/LLINs distributed free of charge	Yes	2012	First-line treatment of unconfirmed malaria	-	-
	ITNs/LLINs distributed to all age groups	Yes	2012	First-line treatment of P. falciparum	CQ+PQ	-
IRS	IRS is recommended	Yes	-	For treatment failure of P. falciparum	AM	-
	DDT is used for IRS	No	-	Treatment of severe malaria	AM	-
Larval control	Use of Larval Control	Yes	-	Treatment of P. vivax	CQ+PQ	-
IPT	IPT used to prevent malaria during pregnancy	NA	-	Dosage of primaquine for radical treatment of P. vivax	0.25 mg/Kg (14 days)	
Diagnosis	Patients of all ages should receive diagnostic test	Yes	1957	Type of RDT used	-	
	Malaria diagnosis is free of charge in the public sector	Yes	-	Therapeutic efficacy tests (clinical and parasitological failure, %)		
Treatment	ACT is free for all ages in public sector	Yes	1957	Medicine	Year	Min
	The sale of oral artemisinin-based monotherapies (oAMTs)	has never been allowed	-	Median	Max	Follow-up
	Single dose of primaquine (0.25 mg base/kg) is used as gametocidal medicine for P. falciparum	Yes	1962	No. of studies	Species	
	Primaquine is used for radical treatment of P. vivax	Yes	1962			
	G6PD test is a requirement before treatment with primaquine	No	-			
	Directly observed treatment with primaquine is undertaken	Yes	1999			
	System for monitoring of adverse reaction to antimalarials exists	No	1962			
Surveillance	ACD for case investigation (reactive)	Yes	2000			
	ACD at community level of febrile cases (pro-active)	Yes	1962			
	Mass screening is undertaken	No	-			
	Uncomplicated P. falciparum cases routinely admitted	No	-			
	Uncomplicated P. vivax cases routinely admitted	No	-			
	Case and foci investigation undertaken					
	Case reporting from private sector is mandatory	Yes	1984			


¹Percent of sites for which resistance confirmed and total number of sites that reported data (n)

²Principal vectors that exhibited resistance


³Class used for malaria vector control in 2017

III. Charts

Sources of financing




Government expenditure by intervention in 2017




IV. Coverage

Coverage of ITN and IRS




Cases tested




V. Impact

Cases tested and treated in public sector




Cases tracked




V. Impact

Confirmed malaria cases per 1000 and ABER



Number of malaria cases



Footnotes
(est.) : WHO estimates based on the survey